• Je něco špatně v tomto záznamu ?

Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model

M. Kripnerová, HS. Parmar, J. Šána, A. Kopková, L. Radová, S. Sopper, K. Biernacki, J. Jedlička, M. Kohoutová, J. Kuncová, J. Peychl, E. Rudolf, M. Červinka, Z. Houdek, P. Dvořák, K. Houfková, M. Pešta, Z. Tůma, M. Dolejšová, F. Tichánek, V....

. 2021 ; 10 (11) : . [pub] 20210525

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21017685

Grantová podpora
PROGRESS Q39 Univerzita Karlova v Praze
PROGRESS Q40/01 Univerzita Karlova v Praze
CZ.02.1.01/0.0/0.0/16_019/0000787 Ministry of Education, Youth and Science
17-17636S Grantová Agentura České Republiky
260 538/2020 Univerzita Karlova v Praze
260 539/2020 Univerzita Karlova v Praze
LM2018132 Ministry of Education, Youth and Science

Sarcomas are a heterogeneous group of mesenchymal tumours, with a great variability in their clinical behaviour. While our knowledge of sarcoma initiation has advanced rapidly in recent years, relatively little is known about mechanisms of sarcoma progression. JUN-murine fibrosarcoma progression series consists of four sarcoma cell lines, JUN-1, JUN-2, JUN-2fos-3, and JUN-3. JUN-1 and -2 were established from a single tumour initiated in a H2K/v-jun transgenic mouse, JUN-3 originates from a different tumour in the same animal, and JUN-2fos-3 results from a targeted in vitro transformation of the JUN-2 cell line. The JUN-1, -2, and -3 cell lines represent a linear progression from the least transformed JUN-2 to the most transformed JUN-3, with regard to all the transformation characteristics studied, while the JUN-2fos-3 cell line exhibits a unique transformation mode, with little deregulation of cell growth and proliferation, but pronounced motility and invasiveness. The invasive sarcoma sublines JUN-2fos-3 and JUN-3 show complex metabolic profiles, with activation of both mitochondrial oxidative phosphorylation and glycolysis and a significant increase in spared respiratory capacity. The specific transcriptomic profile of invasive sublines features very complex biological relationships across the identified genes and proteins, with accentuated autocrine control of motility and angiogenesis. Pharmacologic inhibition of one of the autocrine motility factors identified, Ccl8, significantly diminished both motility and invasiveness of the highly transformed fibrosarcoma cell. This progression series could be greatly valuable for deciphering crucial aspects of sarcoma progression and defining new prognostic markers and potential therapeutic targets.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017685
003      
CZ-PrNML
005      
20210729104000.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm10112297 $2 doi
035    __
$a (PubMed)34070472
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kripnerová, Michaela $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
245    10
$a Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model / $c M. Kripnerová, HS. Parmar, J. Šána, A. Kopková, L. Radová, S. Sopper, K. Biernacki, J. Jedlička, M. Kohoutová, J. Kuncová, J. Peychl, E. Rudolf, M. Červinka, Z. Houdek, P. Dvořák, K. Houfková, M. Pešta, Z. Tůma, M. Dolejšová, F. Tichánek, V. Babuška, M. Leba, O. Slabý, J. Hatina
520    9_
$a Sarcomas are a heterogeneous group of mesenchymal tumours, with a great variability in their clinical behaviour. While our knowledge of sarcoma initiation has advanced rapidly in recent years, relatively little is known about mechanisms of sarcoma progression. JUN-murine fibrosarcoma progression series consists of four sarcoma cell lines, JUN-1, JUN-2, JUN-2fos-3, and JUN-3. JUN-1 and -2 were established from a single tumour initiated in a H2K/v-jun transgenic mouse, JUN-3 originates from a different tumour in the same animal, and JUN-2fos-3 results from a targeted in vitro transformation of the JUN-2 cell line. The JUN-1, -2, and -3 cell lines represent a linear progression from the least transformed JUN-2 to the most transformed JUN-3, with regard to all the transformation characteristics studied, while the JUN-2fos-3 cell line exhibits a unique transformation mode, with little deregulation of cell growth and proliferation, but pronounced motility and invasiveness. The invasive sarcoma sublines JUN-2fos-3 and JUN-3 show complex metabolic profiles, with activation of both mitochondrial oxidative phosphorylation and glycolysis and a significant increase in spared respiratory capacity. The specific transcriptomic profile of invasive sublines features very complex biological relationships across the identified genes and proteins, with accentuated autocrine control of motility and angiogenesis. Pharmacologic inhibition of one of the autocrine motility factors identified, Ccl8, significantly diminished both motility and invasiveness of the highly transformed fibrosarcoma cell. This progression series could be greatly valuable for deciphering crucial aspects of sarcoma progression and defining new prognostic markers and potential therapeutic targets.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Parmar, Hamendra Singh $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Šána, Jiří $u Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 602 00 Brno, Czech Republic
700    1_
$a Kopková, Alena $u Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic $u Department of Pathology, University Hospital Brno, 625 00 Brno, Czech Republic
700    1_
$a Radová, Lenka $u Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Sopper, Sieghart $u Internal Medicine V, Medical University of Innsbruck, 6020 Innsbruck, Austria $u Tyrolean Cancer Research Institute, 6020 Innsbruck, Austria
700    1_
$a Biernacki, Krzysztof $u Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 41-808 Zabrze, Poland
700    1_
$a Jedlička, Jan $u Institute of Physiology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Kohoutová, Michaela $u Institute of Physiology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Kuncová, Jitka $u Institute of Physiology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Peychl, Jan $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Rudolf, Emil $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Červinka, Miroslav $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Houdek, Zbyněk $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Dvořák, Pavel $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Houfková, Kateřina $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Pešta, Martin $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Tůma, Zdeněk $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Dolejšová, Martina $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Tichánek, Filip $u Institute of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
700    1_
$a Babuška, Václav $u Institute of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, 301 66 Plzen, Czech Republic
700    1_
$a Leba, Martin $u Department of Cybernetics, Faculty of Applied Sciences, University of West Bohemia in Pilsen, 301 00 Plzen, Czech Republic
700    1_
$a Slabý, Ondřej $u Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic $u Department of Biology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Hatina, Jiří $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University, 323 00 Plzen, Czech Republic
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 10, č. 11 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34070472 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729103959 $b ABA008
999    __
$a ind $b bmc $g 1676385 $s 1138127
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 10 $c 11 $e 20210525 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
GRA    __
$a PROGRESS Q39 $p Univerzita Karlova v Praze
GRA    __
$a PROGRESS Q40/01 $p Univerzita Karlova v Praze
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000787 $p Ministry of Education, Youth and Science
GRA    __
$a 17-17636S $p Grantová Agentura České Republiky
GRA    __
$a 260 538/2020 $p Univerzita Karlova v Praze
GRA    __
$a 260 539/2020 $p Univerzita Karlova v Praze
GRA    __
$a LM2018132 $p Ministry of Education, Youth and Science
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Možnosti archivace